Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/31493998
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
J Clin Neurosci. 2019 Sep 4. pii: S0967-5868(19)31504-8. doi: 10.1016/j.jocn.2019.08.113. [Epub ahead of print]
Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: A systematic review.
Adiao KJB1, Espiritu AI2, Roque VLA3, Reyes JPBT4.
Subcutaneous immunoglobulin (SCIg) is an emerging therapeutic alternative in the management of myasthenia gravis (MG) due to its potential efficacy, safety, cost effectiveness and ease of administration.
At present, there are no systematic reviews that summarized the effects of SCIg in patients with MG.
The objective of this study is to determine the efficacy and safety of SCIg in the treatment of adult patients with myasthenia gravis. Relevant records were identified from August 2018 to January 2019 systematic search.
Five relevant articles with a total of 34 patients with MG were included in this review. Data on functional disability score and adverse events were obtained.
Based on the included uncontrolled studies, the functional disability scores of adult MG patients after SCIg administration showed consistent improvement. Headache and local site injection reactions were the most common adverse events reported.
The evidence from limited uncontrolled studies gathered in this review showed that SCIg may improve functional disability in patients with MG. Local and mild adverse events were reported with its administration, but no systemic and serious adverse events were noted.
Sur demande de nos donateurs, nous pouvons faire l'acquisition d'un tiré-à-part de l'article intégral
Le coût de USD 35,95 $ est pris en charge par l'Association